What is B. Riley’s Estimate for ATNM FY2025 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Research analysts at B. Riley lowered their FY2025 earnings per share estimates for Actinium Pharmaceuticals in a note issued to investors on Tuesday, April 1st. B. Riley analyst Y. Zhi now forecasts that the company will post earnings of ($0.95) per share for the year, down from their previous estimate of $0.16. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

ATNM has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Stock Down 7.2 %

ATNM stock opened at $1.29 on Thursday. The stock has a 50-day simple moving average of $1.27 and a two-hundred day simple moving average of $1.44. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24. The firm has a market capitalization of $40.24 million, a PE ratio of -0.93 and a beta of -0.27.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after buying an additional 19,843 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after acquiring an additional 11,812 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Actinium Pharmaceuticals by 25.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares in the last quarter. Renaissance Technologies LLC increased its stake in Actinium Pharmaceuticals by 49.9% in the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after acquiring an additional 63,400 shares during the last quarter. Finally, Squarepoint Ops LLC raised its position in Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after purchasing an additional 37,159 shares in the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).